Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs041200054
JPRN-jRCTs041200054
Recruiting
Phase 2

agoya University Pancreatic Tumor Board trial 08 - NUPAT-08

Kodera Yasuhiro0 sites50 target enrollmentOctober 22, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsocally advanced pancreatic cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
ocally advanced pancreatic cancer
Sponsor
Kodera Yasuhiro
Enrollment
50
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 22, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kodera Yasuhiro

Eligibility Criteria

Inclusion Criteria

  • •1\.Locally advanced pancreatic cancer
  • •2\.Age 20\<\= and \<\=79
  • •3\.Performance status 0\-1

Exclusion Criteria

  • •1\.distant metastasis
  • •2\.severe drug allergy
  • •3\.viable multiple primary cancer
  • •4\.gastrointestinal invasion
  • •5\.apparent infectious status
  • •6\.history of abdominal radiotherapy
  • •7\.pregnant or breastfeeding female

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
PAT-07Borderline resectable pancreatic cancerBorderline resectable, pancreatic cancerD021441
JPRN-jRCTs041200028Kodera Yasuhiro50
Active, not recruiting
Not Applicable
A trial comparing the current standard treatment (gemcitabine) to the experimental, combined treatments of gemcitabine plus capecitabine.Resectable pancreatic or peri-ampullary cancersMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10034446Term: Periampullary carcinoma resectableSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2007-004299-38-GBThe University of Liverpool1,396
Active, not recruiting
Phase 1
Comparing Gemcetabine and Capecitabine versus Gemcitabine monotherapy in chemotherapy for pancreatic cancerResectable pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2007-004299-38-DEThe University of Liverpool1,068
Active, not recruiting
Phase 1
European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. - ESPAC-4Resectable pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864
EUCTR2007-004299-38-SEThe University of Liverpool1,080
Active, not recruiting
Not Applicable
European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. - ESPAC-4Resectable pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectable
EUCTR2007-004299-38-FIThe University of Liverpool1,080